Innovent Biologics : China Approves SNDA For CYRAMZA For Hepatocellular Carcinoma Treatment
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Innovent Biologics Inc. said that the National Medical Products Administration or NMPA of China has approved the supplemental New Drug Application or sNDA for CYRAMZA (ramucirumab) in patients with hepatocellular carcinoma (HCC, also known as liver cancer), who have a
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-528809844-ad871f00165f415dbb981507a0010344.jpg "How Do Asset Bubbles Cause Recessions?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1385100656-614bda7570ff4b2aa246f09534212172.jpg "How to Start a Personal Loan Business")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1457697949-38f853bf35c44ad98ee5b5eb5aabd6e7.jpg "7 Ways to Recession-Proof Your Life")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-14539743091-b77fb5e84dc946ad9940191e5c1c6934-67294ee5e02a4303addbf4ceb86dfb79.jpg "US Recessions Throughout History: Causes and Effects")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2003716480-37bf68bd20454cb29efeedec946ae079.jpg "How Shopify and Shop Pay Make Money")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1136785806-623416867e854fe49ccb565bfd3b0025.jpg "The Average 401(k) Balance for a 50-Year-Old May Surprise You. How Do You Compare?")